Arca
Skip to content
Tools
Tools

ABL1, BCR: Bcr/Abl fusion protein

Chimeric protein in Homo sapiens that 9 drugs act on.

  • Drugs that act on it: 9
  • Approved: 6
  • In phases 1 to 3: 3
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on ABL1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 9

Approved6

  • Imatinib
  • Asciminib
  • Nilotinib
  • Ponatinib
  • Bosutinib
  • Dasatinib anhydrous

Phase 32

  • Olverembatinib
  • Radotinib

Phase 21

  • Vodobatinib

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Bcr/Abl fusion protein inhibitor.
    ImatinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor84
    AsciminibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor39
    NilotinibBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitor27
    PonatinibBoxed warningApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor24
    BosutinibApprovedPfizerSmall moleculeInhibitor12
    Dasatinib anhydrousApprovedChia Tai Tianqing PharmaceuticalSmall moleculeInhibitor0
    OlverembatinibPhase 3Ascentage Pharma Group Inc.Small moleculeInhibitor26
    RadotinibPhase 3Il-Yang Pharm. Co., Ltd.Small moleculeInhibitor4
    VodobatinibPhase 2Sun Pharmaceutical IndustriesSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 44 in all, from ClinicalTrials.gov.
    Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)AsciminibPhase 1RecruitingSunil G. IyerNov 13, 2026
    Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaAsciminibPhase 1Not yet recruitingCity of Hope Medical CenterNov 3, 2026
    A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsBosutinib, NilotinibPhase 3RecruitingEnliven TherapeuticsOct 29, 2026
    A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPImatinib, NilotinibPhase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.Oct 21, 2026
    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLOlverembatinibPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaSep 25, 2026
    De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid LeukemiaImatinib, Nilotinib, OlverembatinibPhase 4Not yet recruitingNanfang Hospital, Southern Medical UniversitySep 24, 2026
    Asciminib Frontline Risk AdaptedAsciminibPhase 2Not yet recruitingProf. Dr. med. Andreas HochhausSep 4, 2026
    Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsAsciminibPhase 2RecruitingThomas Ernst, Prof. Dr. med.Aug 27, 2026
    Hyperpolarized MRI for GIST on ImatinibImatinib—Not yet recruitingChang Gung Memorial HospitalJul 24, 2026
    A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibImatinibPhase 2RecruitingGlaxoSmithKlineJul 8, 2026
    A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf RegionAsciminib—Not yet recruitingNovartis PharmaceuticalsJul 2, 2026
    Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent LinesAsciminib—Not yet recruitingGruppo Italiano Malattie EMatologiche dell'AdultoJun 11, 2026
    A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)PonatinibPhase 1RecruitingWake Forest University Health SciencesMay 29, 2026
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLAsciminibPhase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer CenterMay 22, 2026
    A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)ImatinibPhase 3RecruitingGlaxoSmithKlineMay 13, 2026
    Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaImatinibPhase 2RecruitingVictoria Biomedical Research InstituteApr 30, 2026
    A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyAsciminib, Bosutinib, Imatinib, Nilotinib—RecruitingNovartis PharmaceuticalsApr 24, 2026
    Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisImatinibPhase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineApr 15, 2026
    Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNilotinibPhase 2Not yet recruitingThe University of Hong KongMar 25, 2026
    Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLOlverembatinibNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 25, 2026
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLOlverembatinibNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 6, 2026
    Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLOlverembatinibPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 2, 2026
    Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia PatientsNilotinib—Not yet recruitingAssiut UniversityFeb 17, 2026
    Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseOlverembatinib—Enrolling by invitationQian JiangFeb 3, 2026
    Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-worldPonatinib—Not yet recruitingGruppo Italiano Malattie EMatologiche dell'AdultoJan 21, 2026
    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALLPonatinibPhase 2Not yet recruitingUniversity of AlbertaDec 24, 2025
    Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentOlverembatinibPhase 1RecruitingAscentage Pharma Group Inc.Dec 15, 2025
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaPonatinibPhase 2RecruitingUniversity of WashingtonNov 4, 2025
    Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)OlverembatinibPhase 2Not yet recruitingM.D. Anderson Cancer CenterSep 17, 2025
    A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) TherapyBosutinib, Nilotinib—RecruitingNovartis PharmaceuticalsJul 29, 2025
    A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaPonatinibPhase 2 / Phase 3RecruitingAssistance Publique - Hôpitaux de ParisMar 6, 2025
    Using Tumor Models to Determine TreatmentsPonatinibPhase 2RecruitingUniversity Health Network, TorontoFeb 6, 2025
    Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CMLRadotinib—Active, not recruitingIl-Yang Pharm. Co., Ltd.Oct 30, 2024
    Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.PonatinibPhase 2RecruitingNovartis PharmaceuticalsJul 23, 2024
    Study of Olverembatinib (HQP1351) in Patients With CML-CPBosutinibPhase 3RecruitingAscentage Pharma Group Inc.May 21, 2024
    PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLNilotinibPhase 2RecruitingGruppo Italiano Malattie EMatologiche dell'AdultoMay 10, 2024
    The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPPonatinib—RecruitingPeking University People's HospitalApr 30, 2024
    A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).Bosutinib—RecruitingPfizerMar 7, 2024
    A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPBosutinibPhase 3Active, not recruitingNovartis PharmaceuticalsJul 21, 2021
    Asciminib Roll-over StudyBosutinibPhase 4RecruitingNovartis PharmaceuticalsMay 7, 2021
    Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseRadotinibPhase 2Active, not recruitingIl-Yang Pharm. Co., Ltd.Dec 31, 2020
    Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationBosutinibPhase 2Active, not recruitingBaylor College of MedicineNov 12, 2020
    Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)RadotinibPhase 3Active, not recruitingIl-Yang Pharm. Co., Ltd.Oct 29, 2018
    A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsRadotinibPhase 3RecruitingIl-Yang Pharm. Co., Ltd.Mar 9, 2018

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096618, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.